Abstract
Travel restrictions are the current central strategy to globally stop the transmission of the novel coronavirus disease (COVID-19). Despite remarkably successful approaches in predicting the spatiotemporal patterns of the ongoing pandemic, we lack an intrinsic understanding of the travel restriction’s effectiveness. We fill this gap by developing a surprisingly simple measure, country distancing, that is analogical to the effective resistance in series and parallel circuits and captures the propagation backbone tree from the outbreak locations globally. This approach enables us to map the effectiveness of travel restrictions to arrival time delay (ATD) or infected case reduction (ICR) systematically. Our method estimates that 50.8% of travel restrictions as of Apr-4 are ineffective, resulting in zero ATD or ICR worldwide. Instead, by imposing Hubei’s lockdown on Jan-23 and national lockdown on Feb-8, mainland China alone leads to 11.66 [95% credible interval (CI), 9.71 to 13.92] days of ATD per geographic area and 1,012,233 (95% CI, 208,210 −4,959,094) ICR in total as of Apr-4. Our result unveils the trade-off between the country distancing increase and economic loss, offering practical guidance for strategic actsion about when and where to implement travel restrictions, tailed to the real-time national context.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the Department of Mechanical Aerospace and Nuclear Engineering Department at Rensselaer Polytechnic Institute, Troy, NY.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NO clinical trials and interventional study
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data needed to evaluate the conclusions in the paper are presented in this paper. Additional data related to this paper may be requested from the authors.
